16-Year Epidemiologic Study of Chronic Myeloid Leukemia in Azerbaijan: Clinical and Molecular Insights

Aytan Shirinova 1 * , Chingiz Asadov 1, Aypara Hasanova 1, Zohra Alimirzoyeva 1
More Detail
1 National Hematology and Blood Transfusion Center, Baku, Azerbaijan
* Corresponding Author
J CLIN MED KAZ, Volume 23, Issue 2, pp. 6-18. https://doi.org/10.23950/jcmk/18009
OPEN ACCESS 327 Views 300 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, A.S. and C.A.; methodology, A.S., C.A. and A.H.; validation, A.S. and Z.A.; formal analysis, A.S. and A.H.; investigation, A.S., C.A. and Z.A.; resources, C.A.; data curation, A.S. and A.H.; writing – original draft preparation, A.S.; writing – review and editing, A.S., C.A., A.H. and Z.A.; visualization, A.S.; supervision, C.A.; project administration, A.S.; funding acquisition, Not applicable. All authors have read and agreed to the published version of the manuscript.

Data availability statement: All raw data underlying the findings of this study can be obtained from the corresponding author upon reasonable request.

Artificial Intelligence (AI) Disclosure Statement: AI-Unassisted Work.

ABSTRACT

Abstract
Background:
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with a global incidence of 0.5–2 per 100,000 population. However, comprehensive epidemiologic data from Azerbaijan remain limited.
Methods:
A retrospective nationwide cohort study was conducted at the National Hematology and Blood Transfusion Center, the sole hematology referral center in Azerbaijan. All patients diagnosed with CML between 2008 and 2023 were included. Demographic, clinical, molecular, and treatment data were extracted from medical records. Descriptive analyses assessed temporal trends, age and sex distribution, seasonal and geographic patterns, ABO/Rh blood groups, kinase domain mutations, treatment response, and survival.
Results:
Study included 766 patients , with a female predominance (54%) and the highest disease burden observed in individuals aged 50–59 years. CML incidence increased from 0.31 to 0.86 per 100,000 population between 2008 and 2023, while prevalence rose more than twelve-fold. Following the introduction of tyrosine kinase inhibitors (TKIs), five-year overall survival exceeded 80%. Most patients resided in the Absheron region, suggesting possible environmental or industrial influences. New diagnoses were more frequent during summer months (29.6%). Blood group A was more prevalent among patients compared with controls (40.3% vs 35.4%). First-line imatinib achieved optimal molecular responses in approximately 80% of patients, while 15% experienced treatment failure. Among 115 patients tested, T315I was the most common BCR-ABL mutation.
Conclusions:
This nationwide CML analysis from Azerbaijan reveals a rising disease burden, female predominance, and favorable survival outcomes with TKI therapy. The findings emphasize the need for sustained access to molecular diagnostics and support national strategies for equitable CML care.
Keywords: chronic myeloid leukemia, epidemiology, Azerbaijan, molecular mutations, treatment response

CITATION

Shirinova A, Asadov C, Hasanova A, Alimirzoyeva Z. 16-Year Epidemiologic Study of Chronic Myeloid Leukemia in Azerbaijan: Clinical and Molecular Insights. J CLIN MED KAZ. 2026;23(2):6-18. https://doi.org/10.23950/jcmk/18009

REFERENCES

  • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, monitoring, and treatment. American Journal of Hematology. 2023;98(1):95–109. https://doi.org/10.1002/ajh.27443
  • Chaulagain P, Poudel A, Aryal S, Sainatham C, Lutfi F. Global trends of burden of chronic myeloid leukemia based on socio-demographic index (SDI): a comparative epidemiological study. Blood. 2024;144(Suppl 1):7918. https://doi.org/10.1182/blood-2024-210443
  • Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. British Journal of Cancer. 2011;105(11):1684–1692. https://doi.org/10.1038/bjc.2011.450
  • Karantanos T, Jain T, Moliterno AR, Jones RJ, DeZern AE. Sex-related differences in chronic myeloid neoplasms: from the clinical observation to the underlying biology. International Journal of Molecular Sciences. 2021;22(5):2595. https://doi.org/10.3390/ijms22052595
  • Ohyashiki K. Clinical epidemiology [in Japanese]. Nihon Rinsho. 2001;59(12):2416–2420.
  • Asadov Ch, Alimirzayeva Z, Kerimov A. Epidemiology of leukemia in Azerbaijan. Baku: Xazar Universitesi Nesriyyati; 2012.
  • Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O’Brien SG, Druker BJ. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine. 2017;376(10):917–927. https://doi.org/10.1056/NEJMoa1609324
  • Li J, Smith A, Crouch S, Oliver S, Roman E. Estimating the prevalence of hematological malignancies and precursor conditions using data from the Haematological Malignancy Research Network (HMRN). Cancer Causes & Control. 2016;27(8):1019–1026. https://doi.org/10.1007/s10552-016-0780-z
  • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer. 2013;49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027
  • Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O'Neil WM, Saikia TK, Wang J. Chronic myeloid leukemia in Asia. International Journal of Hematology. 2009;89(1):14–23. https://doi.org/10.1007/s12185-008-0230-0
  • Szczepanek E, Chukwu O, Kamińska M, Wysogląd H, Cenda A, Zawada M. Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience. Leukemia & Lymphoma. 2022;63(9):2213–2223. https://doi.org/10.1080/10428194.2022.2068000
  • Maas CCHM, van Klaveren D, Ector GICG, Posthuma EFM, Visser O, Westerweel PE, Janssen JJWM, Blijlevens NMA, Dinmohamed AG. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018. British Journal of Haematology. 2022;196(5):1219–1224. https://doi.org/10.1111/bjh.17989
  • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. American Journal of Hematology. 2022;97(9):1236–1256. doi.org/10.1002/ajh.26642
  • Turhan AG. Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies [in French]. Bulletin du Cancer. 2005;92(1):75–82.
  • Baccarani M, Pileri S, Steegmann JL, Müller M, Soverini S, Dreyling M; ESMO Guidelines Working Group. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012;23(Suppl 7):vii72–vii77. https://doi.org/10.1093/annonc/mds228
  • Usui N. Molecular targeted treatment—new treatment strategy for patients with chronic myeloid leukemia [in Japanese]. Rinsho Byori (Japanese Journal of Clinical Pathology). 2004;52(2):136–144.
  • Shirinova A, Asadov C, Hasanova A, Alimirzoyeva Z. Unique gender-related characteristics and differences of chronic myeloid leukemia patients in Azerbaijan: a retrospective cohort study. Cureus. 2025;17(10):e94677. https://doi.org/10.7759/cureus.94677
  • Illing A, Liu P, Ostermay S, Schilling A, de Haan G, Krust A, Amling M, Chambon P, Schinke T, Tuckermann JP. Estradiol increases hematopoietic stem and progenitor cells independent of its actions on bone. Haematologica. 2012;97(8):1131–1135. https://doi.org/10.3324/haematol.2011.052456
  • Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Rosso S, Forman D, Bray F, Comber H. The European Cancer Observatory: a new data resource. European Journal of Cancer. 2015;51(9):1131–1143. https://doi.org/10.1016/j.ejca.2014.01.027
  • Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H, Jin J, You L. Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Frontiers in Oncology. 2020;10:580759. https://doi.org/10.3389/fonc.2020.580759
  • Aliyeva G, Salamzadeh S. Air pollution and its effects in Baku: a public health perspective. Azerbaijan Medical Journal. 2018;54(2):45–50.
  • Smith MT. Advances in understanding benzene health effects and susceptibility. Annual Review of Public Health. 2010;31:133–148. https://doi.org/10.1146/annurev.publhealth.012809.103646
  • Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA 3rd, Prada D, Samet J, Thurston G, Cohen A. Outdoor air pollution and cancer: an overview of the current evidence and public health recommendations. CA: A Cancer Journal for Clinicians. 2020;70(6):460–479. https://doi.org/10.3322/caac.21632
  • Hassan J, Adil SO, Haider Z, Zaheer S, Anwar N, Nadeem M, Ansari SH, Shamsi T. Seasonal variations in hematological disorders: a 10-year single-center experience. International Journal of Laboratory Hematology. 2021;43(1):93–98. https://doi.org/10.1111/ijlh.13337
  • Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology. 2016;34(24):2851–2857. https://doi.org/10.1200/JCO.2015.66.2866
  • Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, on behalf of the IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758–3765. https://doi.org/10.1182/blood-2010-03-273979
  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy of a specific BCR-ABL tyrosine kinase inhibitor in chronic myeloid leukemia. New England Journal of Medicine. 2001;344(14):1031–1037. https://doi.org/10.1056/NEJM200104053441401
  • Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Mueller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NCP, Martinelli G. BCR-ABL kinase domain mutations and resistance to first- and second-generation tyrosine kinase inhibitors. Blood. 2011;118(15):4010–4015. https://doi.org/10.1182/blood-2010-12-326405
  • Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. New England Journal of Medicine. 2003;349(15):1451–1464. https://doi.org/10.1056/NEJMra020777